Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

5.13
+0.12002.40%
Post-market: 5.130.00000.00%19:30 EDT
Volume:276.57K
Turnover:1.43M
Market Cap:111.31M
PE:-1.60
High:5.54
Open:5.11
Low:4.98
Close:5.01
52wk High:17.94
52wk Low:3.35
Shares:21.70M
Float Shares:11.17M
Volume Ratio:1.66
T/O Rate:2.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2080
EPS(LYR):-0.7400
ROE:-66.02%
ROA:-40.38%
PB:1.49
PE(LYR):-6.93

Loading ...

Aardvark Therapeutics CFO and COO Sun Nelson Disposes of USD 395,790.45 in Common Shares

Reuters
·
Sep 12

Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Major AARD Stock Drops

TIPRANKS
·
Aug 28

Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops

TIPRANKS
·
Aug 21

Aardvark Therapeutics Shareholders Approve Governance and Incentives

TIPRANKS
·
Aug 18

Aardvark Therapeutics Held Annual Shareholder Meeting

Reuters
·
Aug 18

Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)

TIPRANKS
·
Aug 15

PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall

Reuters
·
Aug 13

Grace Therapeutics Q1 Net Loss Widens on Impairment Charges

Reuters
·
Aug 13

Stifel Nicolaus Keeps Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)

TIPRANKS
·
Aug 13

Indaptus Q2 Net Loss Narrows as Costs Fall

Reuters
·
Aug 13

AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges

TIPRANKS
·
Aug 13

Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition

Reuters
·
Aug 13

Aardvark Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains

Reuters
·
Aug 12

Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Douglas AG (OtherDOUDF) and Aardvark Therapeutics, Inc. (AARD)

TIPRANKS
·
Aug 12

Aardvark Therapeutics Q2 Operating Expenses Fall on Paused ARD-101 Clinical Trials and Workforce Reduction

Reuters
·
Aug 12

Aardvark Therapeutics Inc Q2 Net Income USD -14.387 Million VS. Ibes Estimate USD -20.6 Million

THOMSON REUTERS
·
Aug 12

Aardvark Therapeutics Q2 EPS $-0.66

THOMSON REUTERS
·
Aug 12

Aardvark Therapeutics Inc Q2 Operating Expenses USD 15.084 Million

THOMSON REUTERS
·
Aug 12

Aardvark Therapeutics Inc Q2 Income from Operations USD -15.084 Million

THOMSON REUTERS
·
Aug 12